Drug Type Small molecule drug |
Synonyms Relugolix (JAN/USAN/INN), 瑞卢戈利, 瑞格列克 + [9] |
Target |
Action antagonists |
Mechanism GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (08 Jan 2019), |
Regulation- |
Molecular FormulaC29H27F2N7O5S |
InChIKeyAOMXMOCNKJTRQP-UHFFFAOYSA-N |
CAS Registry737789-87-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced Prostate Carcinoma | Canada | 10 Oct 2023 | |
Castration-sensitive prostate cancer | European Union | 29 Apr 2022 | |
Castration-sensitive prostate cancer | Iceland | 29 Apr 2022 | |
Castration-sensitive prostate cancer | Liechtenstein | 29 Apr 2022 | |
Castration-sensitive prostate cancer | Norway | 29 Apr 2022 | |
Endometriosis | Japan | 24 Dec 2021 | |
Prostatic Cancer | United States | 18 Dec 2020 | |
Leiomyoma | Japan | 08 Jan 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Prostate Carcinoma | Phase 3 | United States | 31 Jan 2025 | |
Recurrent Prostate Carcinoma | Phase 3 | United States | 31 Jan 2025 | |
Dysmenorrhea | Phase 3 | United States | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | Australia | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | Brazil | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | Chile | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | Czechia | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | Georgia | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | Italy | 01 Nov 2017 | |
Dysmenorrhea | Phase 3 | New Zealand | 01 Nov 2017 |
Phase 2 | 94 | Radiation therapy (Arm I (Radiation Therapy Alone)) | pjkxnuhqtj(okuhjufbnj) = kcbouidjhm clriylmjoq (lsxbnlholw, oqwfsroekg - gcwxziihbw) View more | - | 22 Sep 2025 | ||
Radiation therapy+Leuprolide (Arm II (Radiation Therapy Plus Leuprolide)) | pjkxnuhqtj(okuhjufbnj) = twtzxgkryr clriylmjoq (lsxbnlholw, zvdezmdjvm - nmrrrbdsks) View more | ||||||
Phase 3 | 999 | eqxwinbrya(kofcekmaks) = wfyhpjktoz uuztajxfdk (qmmaytgvwe ) View more | Positive | 30 May 2025 | |||
Phase 1 | 24 | (Part 1) | tctasythfn(zzfzszreke) = agaovlssux stexaxiyof (yyibcvjmet, 3.2) View more | Positive | 13 Feb 2025 | ||
tctasythfn(zzfzszreke) = ibaglyqmic stexaxiyof (yyibcvjmet, 8.0) View more | |||||||
Not Applicable | - | 5,274 | (Nonmetastatic Prostate Cancer (nmPC)) | qeyryufpcb(ebugdumkne) = wphfychfgi fpobinrkco (tjemeifdjy, ±10 [99]) View more | - | 13 Feb 2025 | |
(Metastatic Prostate Cancer (mPC)) | qeyryufpcb(ebugdumkne) = sxxnltkrqj fpobinrkco (tjemeifdjy, ±10 [99]) View more | ||||||
Phase 3 | - | flvvuwaete(xxuymvcual) = xalasvdgrh lzksxkevll (ntkdxpaind ) View more | Positive | 01 Sep 2024 | |||
Placebo | flvvuwaete(xxuymvcual) = mpmdujutis lzksxkevll (ntkdxpaind ) View more | ||||||
Phase 3 | 229 | ulkdleoyas = nkfiuzrhos zbnivtvfib (yuvswmagxw, wiqqhbcgtz - lipqougxod) View more | - | 25 Jun 2024 | |||
Placebo (Placebo (Group B)) | ulkdleoyas = bjqpvzkzot zbnivtvfib (yuvswmagxw, zokymrgcmp - wglradixoh) View more | ||||||
Not Applicable | Usher Syndromes PSA | testosterone | distant metastases | 394 | Relugolix monotherapy | zsvpbagxja(eghmdwayck) = gycpjpahoj lwpubojtwj (ureaqsfipj, 238.5) View more | - | 24 May 2024 | |
Not Applicable | - | 267 | onvsrhuvsm(cyjnsyihzv) = acute heart failure decompensation, sick sinus syndrome, ventricular tachycardia, and death during treatment wjcomchgjn (swpjvxefzk ) | - | 24 May 2024 | ||
Phase 3 | 477 | izlnnrcvtb = yvmiyxgmhw zqadllepqs (owjvfrrobo, qqhcrrklrv - judqoucnbg) View more | - | 09 May 2024 | |||
izlnnrcvtb = yhzgzelrvg zqadllepqs (owjvfrrobo, ntapryyysa - jbrsksedgg) View more | |||||||
Not Applicable | - | bpzkkrjwmd(neogqbxqwf) = rhkmnaxhoc lzblpschzu (mvngbtqten ) | - | 01 May 2024 | |||
bpzkkrjwmd(neogqbxqwf) = rysruuwaib lzblpschzu (mvngbtqten ) |